Hepatitis/MASH

Recent studies suggested that hepatitis C antiviral drugs may increase the risk of hepatocellular carcinoma.

Top news of the day from across the healthcare landscape.

There are several key therapeutics areas of which to be aware.

Top news of the day from across the health care landscape.

This decision was made based on a review of available phase 2 efficacy data and in consideration of the evolving marketplace and the growing number of treatment options available for patients with chronic HCV infection, including elbasvir and grazoprevir (Zepatier).

Top news of the week from Specialty Pharmacy Times.

Promotion of healthy lifestyle changes are crucial among HIV-positive patients cured of hepatitis C.

Top news of the day from across the healthcare landscape.

Coffee drinking can cut down risk of all-cause mortality in patients with HIV and hepatitis C virus (HCV) by half, according to a 5-year study published in the Journal of Hepatology.

Same-day results increase the number of individuals who get tested and treated for HCV.

Top news of the week from Specialty Pharmacy Times.

Women with the hepatitis C virus have fewer live births and face a higher risk of miscarriage, infertility, gestational diabetes and pre-eclampsia.

With tremendous advancements related to hepatitis B treatment in the last few years, the other types of hepatitis viruses are often overlooked.

Limited proportion of patients with chronic hepatitis C virus received antiviral treatment before the widespread use of direct-acting antivirals.

Top news of the day from across the health care landscape.

Patients with stage 3 kidney disease cured of hepatitis C virus experienced an improvement in kidney function following treatment.

Top news of the day from across the health care landscape.

Sofosbuvir may help improve the kidney function of some patients with hepatitis C virus.

Mother-to-child transmission of hepatitis B virus remains high, despite an effective vaccine.

A bloated hepatitis C drug marketplace causes manufacturer to focus on hepatitis B.

Top news of the week from Specialty Pharmacy Times.

Determining how hepatitis C progresses is important when considering therapies and the associated costs for different patient groups.

This article highlights several key therapeutics areas with Vosevi that every pharmacist should know.

Accelerated fibrosis in women with a hepatitis C/HIV co-infection begins as early as pre-menopausal years.

Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.

A look at the top stories in pharmacy last week.

Patients with psychological and substance use problems are less likely to stay engaged in hepatitis C care.

Top news of the day from across the health care landscape.

Top news of the day from across the healthcare landscape.